View Press Releases

Certara Introduces the D360 Express Data Platform for Biotech R&D

June 23, 2016

Packaged informatics solution reduces research cycle time, delivering faster insights for busy discovery scientists

PRINCETON, NJ - Jun 23, 2016 - Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced the availability of D360 Express. This R&D informatics platform provides scientific data integration, analysis, and visualization in an easy-to-deploy, self-service solution specifically packaged for discovery scientists at small biopharmaceutical companies.

“The feedback that we have received from the 6,500 scientists using D360 has been overwhelmingly positive with regard to the platform’s ability to reduce research cycle times, enabling them to make quicker, more effective decisions,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “Those scientists estimate that by using D360 they have been able to increase by more than 50 percent the time they spend performing pivotal scientific modeling and analysis instead of provisioning data.” 

With D360 Express, Certara has taken the D360 features and benefits that have proven so valuable to larger pharmaceutical R&D groups, and created a solution tailored to the needs of discovery scientists in smaller organizations.

D360 is a scientifically intelligent data access solution for small molecule discovery scientists. It combines data from multiple cheminformatics and bioinformatics databases, allowing users to query those sources in a common GUI. D360 also enables those scientists to visualize their query results and make informed go/no go and next step decisions.

About Certara
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies. For more information, visit www.certara.com.